Integrated Management of Cancer (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 544

Special Issue Editors


E-Mail Website
Guest Editor
Department of Life Sciences, Neuroscience Solutions to Cancer Research Group, Imperial College London, Sir Alexander Fleming Building, South Kensington Campus, London SW7 2AZ, UK
Interests: metastasis; epigenetics; ion channels; pH; diet; nutraceuticals; growth factors; bioelectricity
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Departments of Hematology-Oncology and Urology, Emory University School of Medicine, Atlanta, GA, USA
2. Winship Cancer Institute, Emory University, Atlanta, GA, USA
Interests: soy isoflavones; botanicals; nutrition and cancer; integrative oncology; prostate cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of the Special Issue titled “Integrated Management of Cancer” (https://www.mdpi.com/journal/cancers/special_issues/InteMC).

Whilst new modalities are steadily being introduced for the treatment of cancer, the global incidence of cases continues to rise, and many problems remain in the clinical management of the disease. Increasing evidence suggests that integrated management may offer the best chance of an effective outcome. Fueled by epigenetics, this is the central theme of this Special Issue of Cancers. “Integrated management” takes various forms. Most commonly, it represents the combination of clinical oncology and complementary medicine. The latter includes dietary factors, nutraceuticals, lifestyle issues, and Traditional Chinese Medicine. Unfortunately, ‘complementary medicine’ often suffers from insufficient evidence. Even when specific complementary agents have been tested by themselves, there is often much less information on how a given agent might combine with conventional treatments such as chemotherapy. Thus, we will pay particular attention to the quality of the available evidence, ideally from well-designed clinical trials. Meta-analyses will also be welcome. More broadly, the remit of this SI also includes combination treatments, repurposed drugs, and insights from emerging areas such as artificial intelligence and cancer neuroscience. As Guest Editors and in the tradition of Cancers, we promise a rapid and fair review process. We welcome pre-publication inquiries from prospective authors.

Prof. Dr. Mustafa B. A. Djamgoz
Prof. Dr. Omer Kucuk
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • complementary medicine
  • epigenetics
  • diet
  • nutraceuticals
  • lifestyle
  • hemotherapy
  • radiotherapy
  • biological therapies
  • immunotherapy
  • nanotechnology
  • stem cells
  • repurposed drugs
  • combination treatments

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 234 KiB  
Article
Predictors of Successful Whole-Body Hyperthermia in Cancer Patients: Target Temperature Achievement and Safety Analysis
by Anna Lena Hohneck, Vivien Schmitz-Solheid, Deniz Gencer, Maik Schroeder, Hartmut Riess, Annette Gerhards, Iris Burkholder, Stefan Heckel-Reusser, Julia Gottfried and Ralf-Dieter Hofheinz
Cancers 2025, 17(16), 2716; https://doi.org/10.3390/cancers17162716 - 21 Aug 2025
Viewed by 245
Abstract
Aim: This study aimed to investigate the effectiveness and safety of whole-body hyperthermia (WBH) in cancer patients, identifying predictive factors for successful treatment (reaching target temperature ≥ 38.5 °C) and assessing adverse effects. Methods: We conducted a retrospective analysis of 397 cancer patients [...] Read more.
Aim: This study aimed to investigate the effectiveness and safety of whole-body hyperthermia (WBH) in cancer patients, identifying predictive factors for successful treatment (reaching target temperature ≥ 38.5 °C) and assessing adverse effects. Methods: We conducted a retrospective analysis of 397 cancer patients receiving a total of 855 WBH treatment sessions at a single institution between January 2018 and December 2018. Results: A total of 855 WBH treatments were performed on 397 patients (76.6% female; median age 58 years). The most common cancer types included breast cancer (52.4%), followed by prostate cancer (13.1%) and gynecological cancers (10.6%), with 54.7% of patients having metastatic disease. Target temperature was reached in 90.1% (770 of 855) of sessions, with a median treatment time of 202 min and maximum temperature of 40.4 °C. Common side effects included headache (54.9%), skin reactions (11.7%), and cardiac effects (9.4%), with no serious adverse events. Serum creatinine (p = 0.01, OR 0.30, 95% CI: 0.11–0.78) and secale cornutum/galena co-medication during WBH (p < 0.001, OR 0.26 [0.12, 0.54]) emerged as independent predictors of achieving target temperature in multivariate analysis. Both elevated creatinine levels and the use of secale cornutum/galena were associated with an approximately 70% lower probability of achieving the target temperature. Conclusions: WBH demonstrates safety in cancer patients with high success rates in reaching target temperatures. Both elevated creatinine levels and the use of secale cornutum/galena were associated with a lower chance of reaching the target temperature and thus impacting and predicting WBH success. Full article
(This article belongs to the Special Issue Integrated Management of Cancer (2nd Edition))
Back to TopTop